Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study - JANO.es - ELSEVIER

doi:10.1016/S1470-2045(10)70230-8 | How to Cite or Link Using DOI
Copyright © 2010 Elsevier Ltd All rights reserved.
Permissions & Reprints
Fast track — Articles
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
aq, Thomas C Wright MDar, Ana Puras MDas, Cecilia Ladines Llave MDat, Maria Tzardi MDau, Prof Theodoros Agorastos MDav, Victoria Garcia-Barriola MDaw, Christine Clavel PhDax, Prof Jaume Ordi MDay, Miguel Andújar MDaz, Xavier Castellsagué MDa, b, Gloria I Sánchez PhDba, Andrzej Marcin Nowakowski MDbb, Prof Jacob Bornstein MDbc, Nubia Muñoz MDa, F Xavier Bosch MDa and on behalf of the Retrospective International Survey and HPVnext term Time Trends Study Group

a IDIBELL, Institut Català d'Oncologia-Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain

b CIBER en Epidemiología y Salud Pública, Barcelona, Spain

c DDL Diagnostic Laboratory, Voorburg, Netherlands

d Hospital del Mar, Barcelona, Spain

e Instituto Portugues de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

f Hospital Universitario del Valle, Cali, Colombia

g National Cancer Centre, Seoul, South Korea

h Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru

i Hospital General de México, Facultad de Medicina, Universidad Nacional Autónoma de México, México, México

j Laboratório de Anatomia Patológica e citologia, Associação de Combate ao Câncer do Brasil Central, Hospital Dr Hélio Angotti, PATMED, Uberada, Brazil

k Hospital General de l'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain

l Facultad de Medicina, Universidad de Valencia, Valencia, Spain

m National Cheng Kung University Medical College, Taiwan Association of Gynecologic Oncologists, Tainan, Taiwan

n Hospital de Clínicas José de San Martín, Universidad de Buenos Aires, Buenos Aires, Argentina

o Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Asunción, Asunción, Paraguay

p Polyclinic for Laboratory Diagnostic, University Clinical Centre Tuzla, Tuzla, Bosnia and Herzegovina

q Uganda Makerere University, Kampala, Uganda

r Centro de Oncología Preventiva, Facultad de Medicina, Universidad de Chile, Santiago, Chile

s American University of Beirut Medical Centre, Beirut, Lebanon

t Rudjer Boskovic Institute, Division of Molecular Medicine, Zagreb, Croatia

u Medical School, Department of Pathology, Hacettepe University, Ankara, Turkey

v Cancer Prevention and Relief Society, Raipur, India

w Instituto Nacional de Cancerología, Bogotá, Colombia

x Centro de Investigación Epidemiológica en Salud Sexual y Reproductiva, Hospital General San Juan de Dios, Guatemala, Guatemala

y Lagos University Teaching Hospital Idi-Araba, Lagos, Nigeria

z Barcelona Centre for International Health Research, Hospital Clinic and Universitat de Barcelona, and Manhiça Health Research Centre, Barcelona, Spain

aa University of the Philippines, College of Medicine, Philippine General Hospital, Manila, Philippines

ab Hospital San Agustín, Avilés, Spain

ac Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

ad Faculty of Medicine, Prince of Songkla University, Hat-Yai, Songkhla, Thailand

ae Cancer Institute, Chinese Academy of Medical Sciences and Peking, Union Medical College, Beijing, China

af Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

ag Royal Women's Hospital, University of Melbourne, Melbourne, VIC, Australia

ah Kanazawa University Hospital, Kanazawa, Japan

ai Escuela de Microbiología, Universidad Autónoma de Honduras, Tegucigalpa, Honduras

aj Registre des Tumeurs d'Alger, National Institute of Health, Algiers, Algeria

ak Regina Elena Cancer Institute, Rome, Italy

al Clínica San Carlos, Madrid, Spain

am Fingerland Department of Pathology, Charles University, Faculty of Medicine and Faculty Hospital, Hradec Králové, Czech Republic

an Massachusetts General Hospital, Boston, MA, USA

ao Vrije Universiteit Medical Centre, Amsterdam, Netherlands

ap Faculty of Medicine, Kuwait University, Kuwait City, Kuwait

aq Centro Regional de Oncologia Coimbra, Instituto Português de Oncologia, Coimbra, Portugal

ar New York Presbyterian Hospital, Columbia University Medical Center, New York, NY, USA

as Hospital Virgen del Camino, Pamplona, Spain

at Cervical Cancer Prevention Centre, Cancer Institute (University of the Philippines, College of Medicine, Philippine General Hospital), Manila, Philippines

au Medical School of University of Crete, Crete, Greece

av Aristotle University of Thessaloniki, Thessaloniki, Greece

aw Universidad Central de Venezuela, Caracas, Venezuela

ax Centre Hospitaliere Universitaire Reims, Laboratoire Pol Bouin, Hôpital Maison Blanche, Reims, France

ay CRESIB-Hospital Clínic, Barcelona, Spain

az Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran Canaria, Spain

ba Universidad de Antioquía, Medellín, Colombia

bb Medical University of Lublin, Lublin, Poland

bc Western Galilee Hospital, Nahariya, Israel

Available online 15 October 2010.


Refers to:
HPV genotypes: implications for worldwide cervical cancer screening and vaccination
The Lancet Oncology, In Press, Corrected Proof, Available online 15 October 2010,
Cosette Marie Wheeler
PDF (122 K) |
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6W85-517W84X-2&_user=10&_coverDate=10%2F15%2F2010&_rdoc=1&_fmt=high&_orig=browse&_origin=browse&_zone=rslt_list_item&_cdi=6645&_sort=d&_docanchor=&view=c&_ct=1&_refLink=Y&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=4e4acb6f8b31fd4882bdaafc3358d6d3&searchtype=a


Referred to by:
HPV genotypes: implications for worldwide cervical cancer screening and vaccination
The Lancet Oncology, In Press, Corrected Proof, Available online 15 October 2010,
Cosette Marie Wheeler
PDF (122 K) |
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6W85-517W84X-2&_user=10&_coverDate=10%2F15%2F2010&_rdoc=1&_fmt=high&_orig=browse&_origin=browse&_zone=rslt_list_item&_cdi=6645&_sort=d&_docanchor=&view=c&_ct=1&_refLink=Y&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=4e4acb6f8b31fd4882bdaafc3358d6d3&searchtype=a

Summary
Background

Knowledge about the distribution of human papillomavirus (previous termHPV)next term genotypes in invasive cervical cancer is crucial to guide the introduction of prophylactic vaccines. We aimed to provide novel and comprehensive data about the worldwide genotype distribution in patients with invasive cervical cancer.
Methods

Paraffin-embedded samples of histologically confirmed cases of invasive cervical cancer were collected from 38 countries in Europe, North America, central South America, Africa, Asia, and Oceania. Inclusion criteria were a pathological confirmation of a primary invasive cervical cancer of epithelial origin in the tissue sample selected for analysis of previous termHPVnext term DNA, and information about the year of diagnosis. previous termHPVnext term detection was done by use of PCR with SPF-10 broad-spectrum primers followed by DNA enzyme immunoassay and genotyping with a reverse hybridisation line probe assay. Sequence analysis was done to characterise previous termHPVnext term-positive samples with unknown previous termHPVnext term types. Data analyses included algorithms of multiple infections to estimate type-specific relative contributions.
Findings

22 661 paraffin-embedded samples were obtained from 14 249 women. 10 575 cases of invasive cervical cancer were included in the study, and 8977 (85%) of these were positive for previous termHPVnext term DNA. The most common previous termHPVnext term types were 16, 18, 31, 33, 35, 45, 52, and 58 with a combined worldwide relative contribution of 8196 of 8977 (91%, 95% CI 90–92). previous termHPVnext term types 16 and 18 were detected in 6357 of 8977 of cases (71%, 70–72) of invasive cervical cancer. previous termHPVnext term types 16, 18, and 45 were detected in 443 of 470 cases (94%, 92–96) of cervical adenocarcinomas. Unknown previous termHPVnext term types that were identified with sequence analysis were 26, 30, 61, 67, 69, 82, and 91 in 103 (1%) of 8977 cases of invasive cervical cancer. Women with invasive cervical cancers related to previous termHPVnext term types 16, 18, or 45 presented at a younger mean age than did those with other previous termHPVnext term types (50·0 years [49·6–50·4], 48·2 years [47·3–49·2], 46·8 years [46·6–48·1], and 55·5 years [54·9–56·1], respectively).
Interpretation

To our knowledge, this study is the largest assessment of previous termHPVnext term genotypes to date. previous termHPVnext term types 16, 18, 31, 33, 35, 45, 52, and 58 should be given priority when the cross-protective effects of current vaccines are assessed, and for formulation of recommendations for the use of second-generation polyvalent previous termHPVnext term vaccines. Our results also suggest that type-specific high-risk previous termHPVnext term-DNA-based screening tests and protocols should focus on previous termHPVnext term types 16, 18, and 45.
Funding

Spanish grants from Instituto de Salud Carlos III, Agència de Gestió d'Ajuts Universitaris i de Recerca, Marató de TV3 Foundation, and unrestricted grants from GlaxoSmithKline Biologicals, Sanofi Pasteur MSD, and Merck.
ScienceDirect - The Lancet Oncology, Volume 11, Issue 10, Pages 907-1008 (October 2010)



GINECOLOGÍA
Identifican los principales tipos de VPH responsables del cáncer de cuello uterino
Actualidad Ultimas noticias - JANOes y agencias -
JANO.es y agencias · 18 Octubre 2010 12:10

Más del 90% de los casos de este cáncer están provocados por 8 tipos de virus, según ha descubierto un equipo del Institut Català d’Oncologia.

virus del papiloma humano
Un estudio coordinado por el Grupo de Investigación, Prevención y Control del Cáncer del Institut Català d’Oncologia (ICO-IDIBELL) ha identificado los ocho tipos de virus del papiloma humano (VPH) responsables de más del 90% de todos los casos de cáncer de cuello de útero en el mundo y que deberían ser el objetivo de las vacunas de nueva generación.

La investigación, que se publica hoy en The Lancet Oncology, también ha observado que los tipos 16, 18 y 45 son los más comunes y aparecen en edades más jóvenes que los otros genotipos de alto riesgo. Por ello, "los futuros programas de cribado basados en la detección del genotipo viral deberían considerar estos tres tipos", subrayan los autores del estudio.

Para llegar a esta conclusión, el trabajo ha recopilado más de 10.000 casos de cáncer de cuello de útero diagnosticados en los últimos 60 años en 38 países y ha determinado que los ocho tipos más frecuentemente identificados han sido, de más a menos frecuente, el 16, 18, 45, 33, 31, 52, 58 y 35 que, de forma conjunta, se han detectado en el 91% de todos los casos de cáncer de cuello de útero estudiados.

Por su parte, los tipos 16, 18 y 45 se han registrado en el 75% del subtipo histológico más frecuente de cáncer de cuello de útero, el de células escamosas, y en el 94% de los adenocarcinomas, el segundo tipo histológico más frecuente.

Responsables del cáncer a edades más tempranas
Asimismo, en el estudio también se ha observado que estos tres tipos son los que provocan cáncer en edades más tempranas ya que, de media, los cánceres en mujeres con uno de estos tipos se diagnosticaron cuatro años antes que el resto. Las vacunas disponibles actualmente previenen la infección por los tipos 16 y 18 y, mediante la protección cruzada, parcialmente del 31 y del 45.

En palabras de los autores del estudio, "el hecho de que los casos de cáncer positivos para el tipo 45 aparezcan en mujeres más jóvenes sugiere que los protocolos de cribado basados en detección de tipos virales deberían incluir el análisis de estos tipos".


The Lancet Oncology; doi:10.1016/S1470-2045(10)70230-8
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6W85-517W84X-1&_user=4845034&_coverDate=10/15/2010&_alid=1502321269&_rdoc=1&_fmt=high&_orig=search&_origin=search&_zone=rslt_list_item&_cdi=6645&_sort=d&_docanchor=&view=c&_ct=107&_acct=C000000593&_version=1&_urlVersion=0&_userid=4845034&md5=eee0d485db2a94aa6d1572942c97b3b6&searchtype=a

IDIBELL
IDIBELL

The Lancet Oncology
ScienceDirect - The Lancet Oncology, Volume 11, Issue 10, Pages 907-1008 (October 2010)


Actualidad Ultimas noticias - JANOes y agencias - Identifican los principales tipos de VPH responsables del cancer de cuello uterino - JANO.es - ELSEVIER

Correspondence to: Dr Silvia de Sanjosé, Unit of Infections and Cancer, Cancer Epidemiology Research Program, IDIBELL, Institut Català d'Oncologia-Catalan Institute of Oncology, Gran Via de l'Hospitalet, 199–203, 08907 L'Hospitalet de Llobregat, Barcelona, Spain